Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Acute Coronary Syndrome Market Overview
The Acute Coronary Syndrome Market is projected to reach USD 15.2 Billion by 2032 at 5.3% CAGR during the forecast period 2023-2032. Acute Coronary Syndrome market is Expected to grow at an approximate CAGR of 5.3% during the forecast period. Acute coronary syndrome is a medical disorder in which the heart's blood flow is suddenly slowed or blocked. Myocardial infarction is an example of the acute coronary syndrome. Some of the frequent symptoms of the syndrome include indigestion, dyspnea, diaphoresis, and inexplicable weariness. During the forecast period, the rising prevalence of coronary heart disease and the growing geriatric population are expected to be important drivers of market growth. The acute coronary syndrome market is expected to develop due to factors such as rising diabetes prevalence and a growing obese population. Acute coronary syndrome is a clinical disease in which blood flow through the coronary arteries is reduced as a result of faulty heart muscle function or any damage to the heart muscles. Chest pain, pain or discomfort in one or both arms, shortness of breath, nausea, perspiration, and other symptoms may occur. To diagnose ACS, blood tests or an ECG can be used. ACS is treated with medications and angioplasty. The market is being driven by two key factors: an increase in the geriatric population and an increase in the frequency of heart illnesses. However, the market is projected to be constrained by government restrictions governing drug approval. Lack of knowledge, high therapeutic surgical costs, and poor per capita healthcare spending in medium and low-income countries, on the other hand, are expected to limit Acute Coronary Syndrome market growth over the projection period.
Segmentation
The acute coronary syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into unstable angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and others. On the basis of diagnosis, the market is categorized into blood tests, imaging, stress test, and others. The imaging segment is sub-segmented into Myocardial Perfusion Imaging (MPI), Computerized Tomography (CT) angiogram, echocardiogram, coronary angiogram, and others. On the basis of treatment, the market is segmented into medication, surgery, and others. The medication segment is sub-segmented into thrombolytics, nitroglycerin, antiplatelet drugs, beta blockers, statins, surgery, and others. The antiplatelet drugs segment is further segmented into aspirin, clopidogrel, prasugrel, and others. The beta blockers segment is further segmented into metoprolol, nadolol, and others. The statins segment is further segmented into atorvastatin, simvastatin, and others. The surgery segment is sub-segmented into angioplasty and stenting, coronary bypass surgery, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.
Regional Analysis
The Americas dominates the acute coronary syndrome market owing to the rising prevalence of coronary heart diseases and presence of a well-developed healthcare sector within the region. Moreover, increasing healthcare expenditure and presence of market players within the region boost the market.
Europe stands second in the acute coronary syndrome market due to the increasing availability of funds for research, a huge patient population, and a well-developed healthcare sector. According to the Heart U.K., there were approximately 404,000 hospital admissions due to coronary heart diseases in England during 2012 to 2013. Moreover, growing geriatric and obese population provides favorable backgrounds for market growth within the region.
Asia Pacific is the fastest growing region for the market due to the presence of developing economies such as India, China, Australia, and others within the region. Moreover, a huge patient population, rising healthcare expenditure, and a rapidly developing healthcare sector fuel the market growth.
The Middle East and Africa has the least share in the acute coronary syndrome market. This can be attributed to the low per capita healthcare expenditure and stringent government policies, especially within the African region. On the hand, the Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.
Key players
The key players for the acute coronary syndrome market are Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), and others.Recent Development
BioCardia, Inc. stated in October 2021 that the first patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for refractory angina has been treated in Acute Coronary Syndrome.
The Independent Data Monitoring Committee approved XyloCor Therapeutics' Phase 2 trial of XC001 for refractory angina in July 2021. (IDMC). The greatest dose was given to three people with refractory angina in this study.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
